Metastatic Soft Tissue Sarcoma Clinical Trial
Official title:
An Analysis of the Changes in the Sarcoma Tumor Immune Microenvironment Following Trabectedin
This research trial studies the immune changes following trabectedin in patients with sarcoma that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Analyzing tumor tissue may help to understand the changes in immune cells in or around the tumor or if there is an increase in immune cells in the tumor after receiving trabectedin.
PRIMARY OBJECTIVES:
I. Percentage of tumor tissue in pre- and post-treatment biopsies comprised of T-cells, as
determined by flow cytometry.
SECONDARY OBJECTIVES:
I. To explore additional potential biomarkers including: numbers of tumor associated
macrophage (TAM) in tumor II. To explore additional potential biomarkers including: phenotype
(classically activated macrophages [M1] versus [vs] alternatively activated macrophages [M2])
as characterized by CD163, CD115, CD206 on infiltrating TAM.
III. To explore additional potential biomarkers including: phenotype of T cells infiltrating
tumor (CD4, CD8, markers of CD4 phenotype including FoxP3 and memory).
IV. To explore additional potential biomarkers including: expression T cell inhibitory
markers (PD-1, CTLA-4, TIM3).
V. To explore additional potential biomarkers including: recognition of autologous tumor by
expanded tumor infiltrating lymphocyte lines.
VI. To explore additional potential biomarkers including: in tumor infiltrating lymphocyte
(TIL) expanded from myxoid/round cell liposarcomas, recognition of cancer testis antigens.
OUTLINE:
Patients undergo a biopsy at baseline and then receive trabectedin for up to 4 cycles.
Beginning 1 week after completion of cycle 2 and prior to cycle 3, patients undergo a second
biopsy. Patients who achieve clinical benefit (complete response [CR], partial response [PR],
stable disease [SD]) after the first post-treatment scan and who continue trabectedin for 4
cycles undergo a third biopsy after cycle 4.
After completion of study, patients are followed up for 30 days.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03670069 -
Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas
|
Phase 1 | |
Recruiting |
NCT05075993 -
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03793361 -
Phase II Study of Regorafenib as Maintenance Therapy
|
Phase 2 | |
Completed |
NCT03009201 -
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
|
Phase 1 | |
Recruiting |
NCT03965234 -
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
|
Phase 1/Phase 2 | |
Recruiting |
NCT04028063 -
Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
|
Phase 2 | |
Active, not recruiting |
NCT04200443 -
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT01514188 -
Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma
|
Phase 2 | |
Recruiting |
NCT05711615 -
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
|
Phase 1 | |
Completed |
NCT01574716 -
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
|
Phase 2 | |
Completed |
NCT02500797 -
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
|
Phase 2 | |
Recruiting |
NCT03138161 -
SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03660930 -
Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
|
Phase 1/Phase 2 |